Q1 · MEDICINE
Article
Author: Wiita, Elisee ; Burgos Morón, Estefanía ; Desroses, Matthieu ; Darabi, Masoud ; Lundbäck, Thomas ; Koolmeister, Tobias ; Llona-Minguez, Sabin ; Cazares-Körner, Cindy ; Homan, Evert ; Jemth, Ann-Sofie ; Baranczewski, Pawel ; Sigmundsson, Kristmundur ; Scobie, Martin ; Warpman Berglund, Ulrika ; Valerie, Nicholas C. K. ; Jenmalm Jensen, Annika ; Artursson, Per ; Sanjiv, Kumar ; Loseva, Olga ; Calderón-Montaño, José Manuel ; Almlöf, Ingrid ; Mehdizadeh, Amir ; Fayezi, Shabnam ; Höglund, Andreas ; Mateus, André ; Helleday, Thomas ; Ghassemian, Artin
The dCTP pyrophosphatase 1 (dCTPase) is a nucleotide pool "housekeeping" enzyme responsible for the catabolism of canonical and noncanonical nucleoside triphosphates (dNTPs) and has been associated with cancer progression and cancer cell stemness. We have identified a series of piperazin-1-ylpyridazines as a new class of potent dCTPase inhibitors. Lead compounds increase dCTPase thermal and protease stability, display outstanding selectivity over related enzymes and synergize with a cytidine analogue against leukemic cells. This new class of dCTPase inhibitors lays the first stone toward the development of drug-like probes for the dCTPase enzyme.